RESEARCH_Lab-Flasks-clear-bkgrnd-copy

“As data from our initial trials exploring KEYTRUDA mature, we are encouraged to see durable clinical activity in difficult-to-treat cancers such as small cell lung cancer and malignant pleural mesothelioma, where new treatments are clearly needed,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “With our extensive immuno-oncology research program, we are developing KEYTRUDA across a range of thoracic malignancies, and we have additional studies underway in these two cancer types.”

Read the article: http://www.businesswire.com/news/home/20161206005400/en/Updated-KEYTRUDA%C2%AE-pembrolizumab-Data-Small-Cell-Lung